Lifevantage 2027 Q1 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- For the quarter ended September 30th, 2026, net revenue was $37.1 million, down 22% from $47.6 million in the same period a year ago.
- Revenue declined 22.2% to $29 million in the Americas and 21.2% to $8.2 million in Asia Pacific and Europe; foreign currency negatively impacted revenue by $400,000, or approximately 80 basis points.
- The revenue decline reflected fewer orders from the active consumer base and lower average order size, including lower sales from the Mindbody GLP-1 system, partly offset by LoveBiome product-line sales.
- Subscription-based revenue represented more than 75% of total revenue, and retention metrics for consultants and customers improved compared with the prior year period.
- Gross profit percentage was 75.4%, compared with 79.5% a year ago; adjusted non-GAAP gross profit percentage, excluding the additional inventory allowance related to the mind-body product line, was 78.2%.
- GAAP operating loss was $0.1 million, compared with operating income of $2.3 million; adjusted non-GAAP operating income was $0.9 million, compared with $2.5 million.
- GAAP net loss was $0.2 million, or $0.02 per diluted share, compared with net income of $2.2 million, or $0.17 per diluted share; adjusted non-GAAP net income was $0.6 million, or $0.05 per diluted share, compared with $2.3 million, or $0.18 per diluted share.
- Adjusted EBITDA was $1.9 million, or 5.2% of revenue, compared with $3.9 million, or 8.2% of revenue, a year ago.
- Cash was $13.7 million and the company had no debt as of September 30th; cash from operations was $0.5 million, and the company had access to a $5 million revolving line of credit with no balance outstanding.
- Capital expenditures were $1.2 million, compared with $0.4 million in the prior year period; no shares were repurchased, and $58.5 million remained under the $60 million share repurchase authorization.
- The company announced a quarterly cash dividend of $0.05 per share of common stock, payable on December 15th, 2026, to shareholders of record as of December 1st, 2026.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good day, ladies and gentlemen. Thank you for standing by. Welcome to today's conference call to discuss LifeVantage's first quarter fiscal year 2027 results. At this time, all participants are in a listen-only mode. Following the formal remarks, we will conduct a question-and-answer session. Instructions will be provided at that time for you to queue up. Hosting today's conference will be Reed Anderson with ICR. As a reminder, today's conference is being recorded. Now, I would like to turn the conference over to Mr. Anderson.
Please go ahead. Thank you, and good afternoon, everyone, and welcome to LifeVantage Corporation's conference call to discuss results for the quarter ended September 30, 2026.
On the call today from LifeVantage are Terrence Moorehead, President and Chief Executive Officer, and Carl Aure, Chief Financial Officer. By now, everyone should have access to the earnings release, which went out this afternoon at approximately 4:05 P.M. Eastern Time. If you have not received this release, it is available on the investor relations portion of LifeVantage's website at www.lifevantage.com. This call is being webcast, and a replay will be available on the company's website as well. Before we begin, we would like to remind everyone that our prepared remarks contain forward-looking statements, and management may make additional forward-looking statements in response to your questions. These statements do not guarantee future performance, and therefore, undue reliance should not be placed upon them.
These statements are based on the current expectations of the company's management and involve inherent risks and uncertainties, including those identified in the risk factors section of LifeVantage's most recently filed Forms 10-K and 10-Q. Please note that during today's call, we will discuss non-GAAP financial measures, including results on an adjusted basis. Management believes these financial measures can facilitate a more complete analysis and greater transparency into LifeVantage's ongoing results of operations, particularly when comparing underlying operating results from period to period. We have included reconciliation of these non-GAAP measures with today's release. This call also contains time-sensitive information that is accurate only as of the date of this live broadcast, November 9, 2026. LifeVantage assumes no obligation to update any forward-looking projections that may be made in today's release or call. Now, I will turn the call over to Terrence Moorehead, President and Chief Executive Officer of LifeVantage.
Thank you, Reed, and good afternoon, everyone. Today, I am going to walk you through some of the initial progress we have made and provide a brief outline of our plans moving forward. Carl is going to walk you through our first quarter performance and financials in a few minutes, but I want to use my time today to focus primarily on where we go from here. I have been with LifeVantage for just over 90 days, and during that time, I have taken the opportunity to listen, learn, and work with our consultants, consumers, employees, and board. I joined the company believing LifeVantage had far greater potential than its current scale reflects. After a comprehensive review of the business, I believe that even more strongly today. But we have a lot of work to do.
In the first quarter, our sales saw revenue decline 22% to $37.1 million, and adjusted EBITDA was $1.9 million. The decline was driven by a decrease in both orders and average order, which reinforces our belief that we need to pursue meaningful change, the type of change that we're committed to delivering. Fortunately, we're moving forward from a position of financial stability. We ended the first quarter with $13.7 million in cash, no debt, and positive operating cash flow. We also benefit from strong gross margins, a unique and highly differentiated product line, and a foundation of subscription-based accounts. On our last call, I outlined three priorities needing attention: the brand, our consumer proposition, and operational excellence and productivity.
Over the past 90 days, we've dug deeper and have concluded that we need a comprehensive strategy that reimagines our go-to-market approach, our marketing engine, our competitive proposition, and our cost structure if we want to maximize our potential and be prepared to capture the opportunities that lie ahead. The goal is to transform LifeVantage into a brand-driven, consumer-focused company that leverages digital capabilities to create an expanding community of consumers and brand advocates. Our brand lies at the heart of the transformation. Today, there are thousands of supplement companies essentially selling the same products with the same ingredients and the same benefits to the same consumers. Some offer different forms and features, but beyond their marketing campaigns, many are virtually indistinguishable. LifeVantage, on the other hand, can occupy a much more distinctive space. That's because LifeVantage is built around a fundamentally different proposition.
Rather than simply giving the body more ingredients, more products, and more things to take, we develop products designed to work with the body's own biology and activate natural processes that are clinically proven to improve people's health. That distinction lies at the heart of what differentiates LifeVantage, and it positions the company in a new, growing, and ownable white space as the next generation of health and science. Of course, the challenge is to take our differentiated approach to health and science and turn it into a differentiated consumer proposition and ultimately a differentiated brand. That's the starting point of our strategic roadmap, which has three major components. The first strategic building block focuses on repositioning the company to change the way people think about LifeVantage and to give consumers a reason to care about the brand. That means repositioning LifeVantage as a next-generation nutraceutical company.
That positioning builds on our product's unique ability to activate the body's powerful biological systems to improve people's health. To get started, we're launching a new campaign based on groundbreaking new research that shows how our lead product, Protandim Nrf2, activates the body's natural defense system to protect the body from environmental toxins like microplastics, pesticides, pollution, and more. For the first time, the new campaign uses before and after images that show the positive impact Protandim has on cells affected by specific environmental toxins. It's an exciting new approach designed to create emotional connection with the brand. We start with an important consumer outcome, which in this case is to protect the body from environmental toxins, and we follow up with simple-to-understand visuals that provide scientific proof. Our second strategic building block focuses on reimagining the business proposition to make it easier to discover, engage with, and share LifeVantage.
Our approach is to modernize the business, build new capabilities, and align with the way consumers shop and buy today. To be clear, we're focusing on rethinking the selling proposition to make it simpler, more digital, and more attractive, while at the same time reimagining the consumer journey to strengthen acquisition, retention, referrals, and social engagement. In the second quarter of calendar year 2027, we'll launch our new website and a more modern digital platform in North America, followed by a third quarter 2027 launch of a new consumer-driven business suite for sellers. Our goal is to combine the reach and convenience of an integrated digital ecosystem with the affinity that comes from a community capable of driving engagement around the brand.
Our third strategic building block focuses on expanding beyond our current scale and scope to more aggressively penetrate key markets, expand share in high-potential categories, and identify new growth platforms. I'm not going to discuss details here to preserve our strategic interests. However, the overriding principle is focus. We need to become more selective about where we compete and where we invest. I want to be thoughtful about expectations. It's still early, but we realize we need to reset the economics of the business by creating a more focused, tighter organization with improved efficiency. That work is progressing, so I'm not going to get ahead of myself, and we're not providing formal guidance today. But shareholders should understand that our transformation agenda addresses both sides of the value creation equation.
Finally, before turning the call over to Carl to cover Q1 financials, I want to touch on an additional item that will help our ability to build momentum and strength as we execute our strategy. Starting January 1st, 2027, our fiscal year will align with the calendar year. That means we'll have one calendar for strategy, planning, budgeting, incentives, innovation, commercial activation, and performance management. It's a relatively simple change with significant implications for how we run the company, and the timing is appropriate as January 1st marks the beginning of the next generation of the company that we're building. With that, I'd like to turn the call over to Carl so he can walk you through our financial results in more detail.
Carl? Thank you, Terrence, and good afternoon, everyone.
Let me walk you through our financial results for the quarter ended September 30th, 2026. Please note that I will be discussing our non-GAAP adjusted results where applicable. You can refer to the GAAP to non-GAAP reconciliation in today's press release for additional details. We delivered net revenue of $37.1 million in the current quarter, which was down 22% compared to $47.6 million in the same period a year ago. The decrease was primarily driven by continued downward pressure in the number of orders from our active consumer base and lower average order size, reflecting impacts from the broader macroeconomic environment, as well as lower sales from our MindBody GLP-1 System. These declines were partially offset by sales of the LoveBiome product line, which we acquired in October of 2025.
Foreign currency also negatively impacted revenue by $400,000 in the quarter, or approximately 80 basis points in the quarter. Revenue in the Americas region decreased 22.2% to $29 million, and revenue in the Asia-Pacific and Europe region decreased 21.2% to $8.2 million, including $0.4 million or 3.9% of the negative impact from foreign currency rate fluctuations. Subscription-based revenue continues to provide a substantial portion of our revenue in the quarter, representing more than 75% of total revenue. We also recognize another quarter of improvement in our retention metrics for both consultants and customers in comparison to the prior year period. We will continue to focus on improving our retention metrics as we work on strengthening the brand and improving the consumer proposition during calendar year 2027.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
5 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
